Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsSunpharmaceuticalindustries

    Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More

    Jump to

    • Remain bullish on pharma space: Ajay Bagga

      Ajay Bagga, Market Expert has a bullish view on the pharmaceutical space.

    • Remain invested in Sun Pharma, says Hemen Kapadia

      According to Hemen Kapadia of KR Choksey Securities, one may remain invested in Sun Pharmaceutical Industries.

    • Will stay away from pharma space, says Amit Harchekar

      Amit Harchekar of A Plus Analytics is of the view that one may stay away from the pharma space.

    • Buy Dr Reddy's, opportunities in pharma stocks: Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one can buy Dr Reddy's Laboratories and says that most pharmaceutical companies are buying opportunities on declines.

    • Buy Sun Pharma on every dip, advises Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com recommends buying Sun Pharma on every dip.

    • Aurobindo Pharma top pick, says Phani Sekhar

      P Phani Sekhar of Karvy Stock Broking is of the view that Aurobindo Pharma is the top pick from the pharma space.

    • Prefer Sun Pharma, ICICI Bank: Gaurang Shah

      Gaurang Shah of Geojit BNP Paribas Financial Services is of the view that one may prefer Sun Pharmaceuticals Industries and ICICI Bank.

    • Top buzzing midcap stocks to trade on August 19

      Here are a few top buzzing midcap stocks picked by CNBC-TV18's analysts in trade today. We have - Sun Pharma, Rel Comm, Bharti Airtel, Glenmark Pharma, Jaypee Infra, AurionPro Solutions & Majesco.

    • Opportunity in Sun Pharma, prefer midcap IT: Amit Khurana

      Amit Khurana of Dolat Capital Market is of the view that there is opportunity in Sun Pharma and prefers midcap IT space.

    • Buy Bajaj Holdings; sell Amtek Auto: Ashish Kyal

      Ashish Kyal of wavesstrategy.com recommends buying Bajaj Holdings and Dishman Pharma and advises selling Amtek Auto.

    • Like telecom, oil & gas, financials, pharma: Chhaochharia

      Gautam Chhaochharia, HD-India Research at UBS Securities likes telecom, oil & gas, financials and the pharmaceutical space.

    • Positive on pharma space: Gautam Chhaochharia

      Gautam Chhaochharia, HD-India Research at UBS Securities has a positive view on the pharma space and prefers the bigger names.

    • Top buzzing midcap stocks to trade on August 14

      Here are a few top buzzing midcap stocks picked by CNBC-TV18's analysts in trade today. We have – DLF, Glenmark Pharma, India Bull Hsg, JSPL, Sun Pharma, Canara Bank, Bank Of India, Union Bank, Bank Of Baroda & NTPC.

    • Buy Lupin 1750 Call: VK Sharma

      VK Sharma of HDFC Securities suggests buying Lupin 1750 Call.

    • Positive on pharmaceutical space: Tirthankar Patnaik

      Tirthankar Patnaik - India Strategist at Mizuho Bank is positive on the pharmaceutical space.

    • Positive on pharma, like Aurobindo Pharma: Dipan Mehta

      Dipan Mehta, Member at BSE & NSE is extremely positive on the pharma industry but feels that Sun Pharma will underperform.

    • Go long in Sun Pharma, advises Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com recommends going long in Sun Pharma.

    • Like Sun Pharma, Granules India, Suven Life: Devang Mehta

      Devang Mehta of Anand Rathi Financial Services likes Sun Pharma, Granules India and Suven Lifesciences.

    • Upbeat on Sun Pharma, should buy on dips: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com is upbeat on Sun Pharmaceutical Industries and recommends buying the stock on dips.

    • Pharma will be expensive, may outperform mkt: Sanjay Sinha

      Sanjay Sinha, Founder at Citrus Advisors is of the view that pharma sector will continue to be expensive but may outperform the broader market.

    • Check Out: Super Six stocks for August 6

      Gaurav Bissa of LKP Securities is of the view that one may buy CESC with a target of Rs 620.

    • Buy SBI, ICICI Bank, RIL, Infosys, Sun Pharma: Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one can buy LIC Housing Finance State Bank of India, ICICI Bank, LIC Housing Finance, Infosys, Reliance Industries and Sun Pharmaceutical Industries.

    • Bullish on Infosys, will buy pharma on weakness: IDFC Sec

      Anish Damania, head-Institutional Equities at IDFC Securities has a bullish view on Infosys and feels that one can buy pharma stocks on weakness.

    • Exit Sun Pharma, stock may see volatility: Sukhani

      Sudarshan Sukhani of s2analytics.com recommends exiting Sun Pharmaceutical Industries as the stock may remain volatile.

    • Overweight on pharma, private sector banks: Dipan Mehta

      Dipan Mehta - member at BSE & NSE maintains overweight position on pharma as well as private sector banks.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347